



NHS MEDICAL POLICY

Laser Hair Follicle Destruction for Hidradenitis Suppurativa Procedure 2017-002

Laser hair follicle destruction may be indicated when ALL the following are present:

1	The member has been diagnosed with hidradenitis suppurativa.
2	The hidradenitis suppurativa is documented to be ONE of the following: • Moderate disease or Hurley stage II (recurrent abscesses with sinus tracts and scarring) • Severe disease or Hurley stage III (diffuse involvement with multiple interconnected tracts and abscesses)
3	The member has already tried any 3 of the following treatments in any 2 categories without adequate improvement: • Oral antibiotic (more than one oral antibiotic course using different antibiotics, may be counted as separate treatments) • Oral retinoid (this may include any of the following: acitretin, isotretinoin or alitretinoin) • Hormonal therapy (this may include any of the following: oral contraceptives, cyproterone acetate, spironolactone or finasteride) • Metformin • Cyclosporin • Systemic glucocorticoids • Adalimumab (Humira) • Surgery

SOURCES

1. UpToDate.com was accessed Sep 1, 2017: Hidradenitis suppurativa (acne inversa): Treatment
2. Tierney E, et al, Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. *Dermatol Surg.* 2009;35(8):1188.
3. Xu LY, et al, Histopathologic study of hidradenitis suppurativa following long-pulsed 1064-nm Nd:YAG laser treatment. *Arch Dermatol.* 2011 Jan;147(1):21-8.
4. Jain V and Jain A, Use of Lasers for the Management of Refractory Cases of Hidradenitis Suppurativa and Pilonidal Sinus. *J Cutan Aesthet Surg.* 2012 Jul-Sep; 5(3): 190–192.
5. Highton L, et al, Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. *Plast Reconstr Surg.* 2011 Aug;128(2):459-65.
6. Lee RA, Eisen DB. Treatment of hidradenitis suppurativa with biologic medications. *Journal of the American Academy of Dermatology* 2015;73(5 Suppl 1):S82-8.
7. Ingram JR, et al. Interventions for hidradenitis suppurativa. *Cochrane Database of Systematic Reviews* 2015, Issue 10.
8. Zouboulis CC, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. *Journal of the European Academy of Dermatology and Venereology: JEADV.* 2015;29(4):619-44.
9. Kimball AB, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. *New England Journal of Medicine* 2016;375(5):422-34.
10. Martorell A, et al. An update on Hidradenitis Suppurativa (Part I): Epidemiology, clinical aspects, and definition of disease severity. *Actas Dermo-Sifiliograficas* 2015;106(9):703-15.
11. Personal Conversation: Dr. Stanley Tyler Hollmig, Stanford University Medical Center, Department of Dermatology, Sep 7, 2017 (C. Reynoso, MD)

CODE REFERENCE (This may not be a comprehensive list of codes to apply to this policy.)

17999

POLICY HISTORY/REVISION INFORMATION

Date	Action/Description
09/12/2018	Annual review and approval by UM Committee
09/12/2019	Annual review and approval by UM Committee
09/10/2020	Annual review and approval by UM Committee
09/10/2021	Annual review and approval by UM Committee
09/19/2022	Annual review and approval by UM Committee
08/23/2023	Annual review and approval by UM/QM Committee
08/23/2024	Annual review and approval by UM/QM Committee
06/27/2025	Annual review and approval by UM/QM Committee
06/25/2026	Annual review and approval by UM/QM Committee